Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) insider Robert B. Jones bought 400,000 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The stock was bought at an average price of $0.10 per share, with a total value of $40,000.00. Following the acquisition, the insider now directly owns 412,555 shares in the company, valued at approximately $41,255.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) traded down $0.01 during trading on Friday, reaching $0.33. 60,615 shares of the company traded hands, compared to its average volume of 15,868. Acura Pharmaceuticals, Inc. has a 12-month low of $0.33 and a 12-month high of $1.40. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.23 and a quick ratio of 1.23.

Acura Pharmaceuticals (OTCMKTS:ACUR) last posted its earnings results on Monday, November 13th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. The company had revenue of $0.08 million during the quarter. Acura Pharmaceuticals had a negative net margin of 36.20% and a negative return on equity of 231.18%.

Separately, ValuEngine upgraded shares of Acura Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.

COPYRIGHT VIOLATION NOTICE: This story was reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at

About Acura Pharmaceuticals

Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.

Receive News & Ratings for Acura Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals and related companies with's FREE daily email newsletter.